GSE63857 3 V 1 TAMOXIFEN MOUSE DN (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE63857 3 V 1 TAMOXIFEN MOUSE DN.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE63857 3 V 1 TAMOXIFEN MOUSE DN.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE63857 3 V 1 TAMOXIFEN MOUSE DN.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE63857 3 V 1 TAMOXIFEN MOUSE DN.

Results found

Linked to

 

Label

Description

 

Gene

SRC kinase signaling inhibitor 1

Gene

GTP binding protein 6

Gene

aldehyde dehydrogenase 1 family member L1

Gene

DNA polymerase delta 3, accessory subunit

Gene

CXXC repeat containing interactor of PDZ3 domain

Gene

TruB pseudouridine synthase family member 2

Gene

zinc finger protein 32

Gene

zDHHC palmitoyltransferase 4

Gene

synaptotagmin 12

Gene

proline rich nuclear receptor coactivator 2

  • Gene

    SRC kinase signaling inhibitor 1


  • Gene

    GTP binding protein 6


  • Gene

    aldehyde dehydrogenase 1 family member L1


  • Gene

    DNA polymerase delta 3, accessory subunit


  • Gene

    CXXC repeat containing interactor of PDZ3 domain


  • Gene

    TruB pseudouridine synthase family member 2


  • Gene

    zinc finger protein 32


  • Gene

    zDHHC palmitoyltransferase 4


  • Gene

    synaptotagmin 12


  • Gene

    proline rich nuclear receptor coactivator 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.